Solving COVID: November 11, 2020

Pfizer vaccine works better than expected, FDA approves antibody treatment, and more

Pfizer.
(Image credit: Illustrated | Getty Images, iStock)

1. Pfizer COVID-19 vaccine candidate over 90 percent effective in interim analysis

A coronavirus vaccine candidate in development from Pfizer and BioNTech was found to be more than 90 percent effective against COVID-19 in a first interim analysis, the companies announced on Monday. In an analysis of 94 subjects infected with the coronavirus, the companies said that the early data "indicates a vaccine efficacy rate above 90 percent." This was a better rate than anticipated. Pfizer previously said it could seek emergency use authorization from the Food and Drug Administration for its vaccine candidate later in November, and Pfizer CEO Albert Bourla on Monday said "today is a great day for science and humanity," adding, "We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks."

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More